Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Carbidopa:MCnc:Pt:Ser/Plas:Qn

Known as: carbidopa:concentración de masa:punto en el tiempo:suero/plasma:cuantitativo:, Carbidopa:Mass Concentration:Point in time:Serum/Plasma:Quantitative, Carbidopa [Mass/volume] in Serum or Plasma 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
BACKGROUND Despite decades of research, neurodegenerative disorders like Parkinson's disease remain a leading cause of disability… Expand
Is this relevant?
Review
2019
Review
2019
INTRODUCTION We have performed a systematic literature review to evaluate the current evidence of the pharmacokinetic (PK… Expand
Is this relevant?
2012
2012
AIM To verify the potential role and feasibility of carbidopa premedication in pediatric patients undergoing ¹⁸F-DOPA (Fluorine… Expand
Is this relevant?
2011
2011
A 48-year-old woman arrived at the emergency department with a decreased level of consciousness after having had a generalized… Expand
Is this relevant?
2006
2006
BACKGROUND Motor fluctuations are a common complication in patients with Parkinson disease (PD) receiving long-term levodopa… Expand
Is this relevant?
2005
2005
Lithium elicits opposite effects on two behavioural syndromes in rats: enhancement of the 5-HT1A-linked serotonin syndrome and… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1986
1986
The effect of doubling carbidopa intake on single dose bioavailability of l-Dopa was examined in five parkinsonian patients… Expand
Is this relevant?
1985
1985
The effect of doubling carbidopa intake on single dose bioavailability of L-Dopa was examined in five parkinsonian patients… Expand
Is this relevant?